Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRUN study of docetaxel + ramucirumab after immune checkpoint inhibitor therapy in advanced non-small cell lung cancer
jRCT1051190091Phase 2Completed
- Start
- May 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and ramucirumab in non-small cell lung cancer (NSCLC). Primary endpoint: Overall response rate. Started May 2020; status: completed.
02
Drugs
docetaxelramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1051190091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051190091.